Cardinal Health Reports 19% Revenue Growth to $65.6 Billion in Latest Quarter

Cardinal Health, Inc. reported significant financial growth in its latest 10-Q filing for the quarter ending December 31, 2025. The company achieved total revenue of $65.6 billion for the three months, a 19% increase from $55.3 billion in the same period last year. For the six months, revenue rose 20% to $129.6 billion compared to $107.5 billion in the prior year. The Pharmaceutical and Specialty Solutions segment was a major contributor, generating $60.7 billion in revenue, up 19% year-over-year, driven by growth in branded and specialty pharmaceutical sales. The Global Medical Products and Distribution segment also saw a modest increase of 3% to $3.3 billion for the quarter.

The company's gross margin improved significantly, increasing 23% to $2.4 billion for the three months and $4.7 billion for the six months ended December 31, 2025. This growth was attributed to the acquisitions of Advanced Diabetes Supply (ADS) and other managed service organizations (MSOs), as well as increased contributions from branded and specialty pharmaceutical products. However, the cost of products sold also rose, reflecting the revenue growth, with costs increasing 19% to $63.2 billion for the quarter.

In terms of strategic developments, Cardinal Health completed several acquisitions, including Solaris Health for approximately $1.9 billion, which is expected to enhance its capabilities in the urology market. The company also acquired ADS for $1.0 billion and GI Alliance for $2.8 billion, further expanding its service offerings. These acquisitions are anticipated to contribute positively to future revenue and profitability. The company reported a total segment profit of $903 million for the quarter, a 35% increase from the previous year, with the Pharmaceutical and Specialty Solutions segment alone contributing $687 million, up 29%.

Operationally, Cardinal Health's employee headcount remained stable, and the company reported a cash and equivalents balance of $2.8 billion as of December 31, 2025, down from $3.9 billion at the end of June 2025. The company generated $1.7 billion in net cash from operating activities during the six months, despite significant payments related to opioid litigation settlements totaling $403 million. Cardinal Health's outlook remains positive, with expectations for continued growth driven by its strategic acquisitions and expanding market presence, although it will need to manage its debt levels, which increased to $9.0 billion following the recent acquisitions.